Rheumatoid arthritis, multiple sclerosis and lupus: key points from the COVID-19 era
DOI:
https://doi.org/10.18203/2320-6012.ijrms20231645Keywords:
SARS-CoV-2, Multiple sclerosis, Rheumatoid arthritis, Systemic lupus erythematosus, ImmunosuppressorsAbstract
The purpose of this work was to analyse published data on rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and multiple sclerosis (MS) and SARS-CoV-2 infection: susceptibility, post-infection autoimmune disease (AD) exacerbation, immunosuppressive therapies and long COVID. Supported by PICO strategy, two independent reviewers conducted the research in the PubMed/Medline database from January 2020 to June 2022 and included 16 articles on RA, 25 on MS and 12 on SLE. The quality assessment of the studies was performed using criteria from the National Institute of Health. Patients with RA or SLE had increased susceptibility to contracting SARS-CoV-2. It was higher in RA and increased with the patients’ comorbidities. For MS, susceptibility to SARS-CoV-2 was similar to the general population. Post-infection AD exacerbation occurred in AR, SLE and MS with an increased number of hospitalisations and deaths. Regarding therapies, in RA the use of glucocorticoids (GC) was associated with a worsening of the infection. A more severe clinical picture was associated with anti-CD20 in SLE and with anti-CD20 and methylprednisolone in MS. Considering long COVID, RA and SLE patients had a higher risk of complications opposite to MS patients. There was a higher susceptibility to SARS-CoV-2 infection in rheumatological diseases AR and SLE, exacerbated by age and comorbidities. For RA and MS, GC aggravated the infection and for SLE and MS anti-CD20 antibodies use. In all AD there was exacerbation and worsening of the clinical picture translated in long COVID, the latter with MS exception.
Metrics
References
WHO. Fact sheet: WHO Coronavirus (COVID-19) Dashboard. Available at: https://covid19.who.int/. Accessed on 14 March 2023.
Tan EH, Sena AG, Prats-Uribe A. COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. Rheumatology (Oxford). 2021;60:37-50.
Li J, Hu H. Liu XD, Yin CC, Li J. COVID-19 illness and autoimmune diseases: recent insights. Inflamm Res. 2021;70(4):407-28.
Fu XL, Qian Y, Jin XH, Yu HR, Du L, Wu H, et al. COVID-19 in patients with systemic lupus erythematosus: A systematic review. Lupus. 2022;31(6):684-96.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):1000097.
NIH. Fact sheet: Study Quality Assessment Tools. Available at: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed on 14 March 2023.
Wang P, Ni J, Chu YY, Chen Q, Wu G, Fang Y, et al. Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis. Biomed Pharmacother. 2022;150:112997.
El-Malky AM, Albalawi YAS, Alanazi SM, Albalawi MAS, Althobaiti AN, Kassarah ZAA, et al. Severe acute respiratory syndrome coronavirus 2 and risk of inhospital mortality among end-stage renal disease patients with rheumatoid arthritis: A scientific perspective, Saudi J Kidney Dis Transpl. 2021;32(2):468-80.
Wang Y, D'Silva KM, Jorge AM, Li X, Lyv H, Wei J, et al. Increased risk of COVID-19 in Patients with rheumatoid arthritis: a general population-based cohort study Arthritis Care Res (Hoboken). 2022;74(5):741-7.
Nørgård B.M., F.D. Zegers, J. Nielsen, J. Kjeldsen, Post COVID-19 hospitalizations in patients with chronic inflammatory diseases - A nationwide cohort study, J Autoimmun 125 (2021) 1-8.
Jung Y., M. Kwon, H.G. Choi, Association between previous rheumatoid arthritis and COVID-19 and its severity: a nationwide cohort study in South Korea, BMJ Open 11(10) (2021) 1-7.
Tuna HI, Alparslan GB, Yilmaz S. Pain and affected symptoms of patients with rheumatoid arthritis during COVID-19 period. pain management nursing. Am Soc Pain Manage Nurse. 2022;23(1):43-7.
Bartels LE, Ammitzbøll C, Andersen JB, Vils SR, Mistegaard CE, Johannsen AD, et al. Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int. 2021;41(11):1925-31.
Raiker R, DeYoung C, Pakhchanian H, Ahmed S, Kavadichanda C, Gupta L, et al. Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States. Semin Arthritis Rheum. 2021;51(5):1057-66.
Mahdavi MA, Varshochi M, Hajialilo M, Dastgiri S, Khabbazi R, Khabbazi A. Factors associated with COVID-19 and its outcome in patients with rheumatoid arthritis. Clin Rheumatol. 2021;40(11):4527-31.
Sparks JA, Wallace ZS, Seet AM. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021;80(9):1137-46.
Migkos MP, Kaltsonoudis E, Pelechas E, Drossou V, Karagianni PG, Kavvadias A, et al. Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience. Rheumatol Int. 2021;41(5):903-9.
Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021;7(1):1-8.
Wong AY, MacKenna B, Morton CE, Schultze A, Walker AJ, Bhaskaran K, et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an Open SAFELY cohort analysis based on two cohorts. Ann Rheumat Dis. 2021;80(7):943-51.
Loarce-Martos J, García-Fernández A, López-Gutiérrez F, García-García V, Calvo-Sanz L, Del Bosque-Granero I, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int. 2020;40(12):2015-21.
Pablos JL, Galindo M, Carmona L. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study, Ann Rheum Dis. 2020;79(12):1544-9.
Montero F, Martínez-Barrio J, Serrano-Benavente B, González T, Rivera J, Collada JM, et al. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int. 2020;40(10):1593-8.
Manzano GS, Rice DR, Klawiter EC, Matiello M, Gillani RL, Tauhid SS, et al. Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study. Multiple Sclerosis. 2022;28(7):1146-50.
Smith TE, Madhavan M, Gratch D, Patel A, Saha V, Sammarco C, et al. Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies. Multip Scleros Related Disord. 2022;60:103735.
Alroughani R, Inshasi J, Al-Hashel J, Alkhaboury J, Alsalti A, Suwaidi RA, et al. Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East, J Clin Neurosci. 2022;99:311-6.
Paybast S, Hejazi SA, Molavi P, Habibi MA, Moghadasi NA. (2022). A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran. Multip Scleros Relat Disord. 2022;60:103712.
Madelon N, Heikkilä N, Royo, I, Fontannaz P, Breville G, Lauper K, et al. Omicron-specific cytotoxic t-cell responses after a third dose of mRNA COVID-19 vaccine among patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol. 2022;79(4):399-404.
Ghadiri F, Sahraian MA, Azimi A, Moghadasi AN. The study of COVID-19 infection following vaccination in patients with multiple sclerosis. Multip Scleros Relat Disord. 2022;57:103363.
Zabalza A, Arrambide G, Tagliani P. Humoral and cellular responses to SARS-CoV-2 in convalescent COVID-19 patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;9(2):1143.
Solomon JM, Jones A, Hohol M, Krysko KM, Muccilli A, Roll A, et al. Clinical characteristics and outcomes of multiple sclerosis patients with COVID-19 in Toronto, Canada. Multip Scleros Rela Disord. 2022;58:103509.
Briggs FBS, Mateen FJ, Schmidt H. COVID-19 vaccination reactogenicity in persons with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021;9(1):1104.
Zakaria M, Ponzano M, Schiavetti I, Carmisciano L, Nada M, AbdelNaseer M, et al. The MuSC-19 study: the Egyptian cohort. Multip Scleros Relat Disord. 2021;56:103324.
Simpson-Yap S, De Brouwer E, Kalincik T, Rijke N, Hillert JA, Walton C, et al. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurol. 2021;97(19):1870-85.
Alshamrani F, Alnajashi H, AlJumah M, Almuaigel M, Almalik Y, Makkawi S, et al. Registry of patients with multiple sclerosis and COVID-19 infection in Saudi Arabia. Mult Scler Relat Disord. 2021;52:1-6.
Kempen ZLE, Strijbis EMM, Al MMCT, Steenhuis M, Uitdehaag BMJ, Rispens T, et al. SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort. JAMA Neurol. 2021;78(7):880-2.
Salter A, Fox RJ, Newsome SD, Halper J, Li DKB, Kanellis P, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis. JAMA Neurol. 2021;78(6):699-708.
Khedr EM, Abo-Elfetoh N, Deaf E, Hassan HM, Amin MT, Soliman RK, et al. Surveillance study of acute neurological manifestations among 439 Egyptian patients with COVID-19 in Assiut and Aswan University Hospitals. Neuroepidemiology. 2021;55(2):109-18.
Mallucci G, Zito A, Baldanti F, Gastaldi M, Fabbro BD, Franciotta D, et al. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients. Multip Scleros Relat Disord. 2021;49:102754.
Sormani MP, Rossi ND, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021;89(4):780-9.
Maillart E, Papeix C, Lubetzki C, Roux T, Pourcher V, Louapre C. Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies? Multip Scleros Relat Disord. 2020;46:102482.
Sahraian MA, Azimi S, Navardi S, Ala A, Moghadasi N. Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord. 2020;46:1-6.
Mantero V, Abate L, Balgera R, Basilico P, Salmaggi A, Cordano C. Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients. Multip Scleros Relat Disord. 2020;46:102453.
Parrotta E, Kister I, Charvet L, Sammarco C, Saha V, Charlson RE, et al. COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center. Neurology Neuroimmunol Neuroinflammat. 2020;7(5):835.
Costa G, Leocani L, Montalban X, Guerrero AI, Sørensen PS, Magyari M, et al. Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. Ital Soc Clinic Neurophysiol. 2020;41(7):1647-50.
Meca-Lallana V, Aguirre C, Río B, Cardeñoso L, Alarcon T, Vivancos J. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies. Multip Scleros Relat Disord. 2020;44:102306.
Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran, Mult Scler Relat Disord. 2020;43:1-6.
Sormani MP. Real-world studies provide reliable comparisons of disease modifying therapies in MS - No. Multiple Sclerosis. 2020;26(2):161-2.
Mageau A, Papo T, Ruckly S, Strukov A, Gysel DV, Sacre K, et al. Survival after COVID-19-associated organ failure among inpatients with systemic lupus erythematosus in France: a nationwide study. Ann Rheum Dis. 2022;81(4):569-74.
Zavala-Flores E, Salcedo-Matienzo J, Quiroz-Alva A, Berrocal-Kasay A. Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. Clinic Rheumatol 2022;41(5):1349-57.
Barbhaiya M, Levine JM, Siegel CH, Bykerk VP, Jannat-Khah D, Mandl LA. Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. Clinic Rheumatol. 2022;41(5):1619-22.
Raiker R, Pakhchanian H, DeYoung C, Gupta L, Kardeş S, Ahmed S, et al. Short term outcomes of COVID-19 in lupus: Propensity score matched analysis from a nationwide multi-centric research network. J Autoimmun. 2021;125:1-7.
Sjöwall J, Azharuddin M, Frodlund M, Zhang Y, Sandner L, Dahle C, et al. SARS-CoV-2 antibody isotypes in systemic lupus erythematosus patients prior to vaccination: associations with disease activity, antinuclear antibodies, and immunomodulatory drugs during the first year of the pandemic. Front Immunol. 2021;12:724047.
Ramirez GA, Argolini LM, Bellocchi C, Moroni L, Della-Torre E, Farina N, et al Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year. Clinic Immunol. 2021;231:108845.
Schioppo T, Argolini LM, Sciascia S, Pregnolato F, Tamborini F, Miraglia P, et al. Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients, Rheumatology (Oxford). 2022;61(5):1928-35.
Espinosa G, Prieto-González S, Llevadot M, Marco-Hernández J, Martínez-Artuña A, Pérez-Isidro A, et al. The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia. Clinic Rheumatol. 2021;40(5):2057-63.
Zucchi D, Tani C, Elefante E, Stagnaro C, Carli L, Signorini V, et al. Impact of first wave of SARS-CoV-2 infection in patients with Systemic Lupus Erythematosus: Weighting the risk of infection and flare, PLoS One. 2021;16(1):1-8.
Pablos JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheumat Dis. 2020;79(12):1544-9.
Montero F, Martínez-Barrio J, Serrano-Benavente B, González T, Rivera J, Collada J, et al. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int. 2020;40(10):1593-8.
Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann Rheum Dis. 2020;79(7):859-66.
Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments, Infect Dis (Lond). 2021;53(10):737-54.
Chisari CG, Toscano S, Arena S, Finocchiaro C, Montineri A, Patti F. Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series. BMC Neurol. 2021;21(1):462.
Ferri C, Giuggioli D, Raimondo V. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. Clin Rheumatol. 2020;39(11):3195-204.
Figueroa-Parra G, Gilbert EL, Valenzuela-Almada MO, Vallejo S, Neville MR, Patel NJ, et al. Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study. Lancet Rheumatol. 2022;4(11):765-74.
Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, et al. COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet. 2022;18(11):1010253.
Brito-Zerón P, Sisó-Almirall A, Flores-Chavez A, Retamozo S, Ramos-Casals M. SARS-CoV-2 infection in patients with systemic autoimmune diseases. Clin Exp Rheumatol. 2021;39(3):676-87.
Goldman JD, Robinson PC, Uldrick TS, Ljungman P. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J Immunother Cancer. 2021;9(6):002630.
Ishak A, Mehendale M, AlRawashdeh MM. The association of COVID-19 severity and susceptibility and genetic risk factors: A systematic review of the literature. Gene. 2022;836:146674.
Dewanjee S, Kandimalla R, Kalra RS, Valupadas C, Vallamkondu J, Kolli V, et al. COVID-19 and rheumatoid arthritis crosstalk: emerging association. Therapeut Option Challeng Cells. 2021;10(12):1-21.
Elemam NM, Maghazachi AA, Hannawi S. COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies. Curr Med Res Opin. 2021;37(6):929-38.
Akiyama S, Hamdeh S, Micic D. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheumat Dis. 2021;80:384-91.
Sawalha AH, Zhao M, Coit P, Lu Q. Epigenetic dysregulation of ACE2 and interferon -regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol. 2020;215:108410.
Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rúa-Figueroa Í, Gonzalez-Gay MA, et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheumat Dis. 2020;79(7):988-90.
American College of Rheumatology. A.C.R. Rheumatology, Rheumatoid Arthritis. Available at: https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Rheumatoid-Arthritis. Accessed on 15 March 2023.
Kristin M, Zachary S. COVID-19 and rheumatoid arthritis. Curr Opin Rheumatol. 2021;33(3):255-61.
Ponzano M, Schiavetti I, Bovis F. A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis. Mult Scler Relat Disord. 2022;63:103909.
Pelechas E, Drossou V, Voulgari PV, Drosos AA. Anti-Rheumatic drugs may ameliorate the clinical course and outcome of COVID-19 in rheumatoid arthritis patients. Mediterr J Rheumatol. 2022;33(1):68-74.
Patel NJ, D’Silva KM, Hsu TY. Coronavirus disease 2019 outcomes among recipients of anti-CD20 monoclonal antibodies for immune-mediated diseases: a comparative cohort study. ACR Open Rheumatol. 2022;4:238-46.
Yusof MY, Arnold J, Saleem B. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study. Lancet Rheumatol. 2023;5(2):88-98.
National Institutes of Health's Coronavirus Disease (COVID-19) Treatment Guidelines. (NIHD) COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/. Accessed on 15 March 2023.
Ferini-Strambi L, Salsone M. COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable? J Neurol. 2021;268(2):409-19.
Downloads
Published
How to Cite
Issue
Section
